Roche Diabetes Care at EASD 2019

September 16 – 20, 2019 | Barcelona, Spain

Order Publications and Solution Brochures

Exhibit Info

Exhibit Info

We look forward to welcoming you to the Roche Diabetes Care exhibition stand! Find out at the stand how we at Roche Diabetes Care connect the dots, so people with diabetes and their caregivers can put their data to meaningful use.

Conference Location:

Fira Barcelona Gran Via (south entrance)

Av. Joan Carles I, 64

08908 L’Hospitalet de Llobregat

Exhibition:

Hall 2


Stand number:

D.06

Opening hours:

Tuesday, September 17: 9:00 – 16:30

Wednesday, September 18: 9:30 – 16:30

Thursday, September 19: 9:30 – 16:30

Location map:

Roche Diabetes Care Symposium

Integrated Personalized Diabetes Management: Connecting the dots to improve outcomes

Monday, October 1
Time: 14:30 -17:00

Messe Berlin, Ehrlich Hall

Chairs: Petra-Maria Schumm-Draeger (Germany), Rolf Hinzmann (Roche Diabetes Care, Germany)

Speaker

Algorithms in medicine: Current use, challenges and the future potential

Daniel Sonntag

German Research Center for Artificial Intelligence

Saarbrücken, Germany

New digital solution support to seize the benefits of integrated Personalised Diabetes Management

Ralph Ziegler

Praxis Dr. med. Ralph Ziegler und Kollegen

Diabetes Clinic for Children and Adolescents

How digital solutions can make a difference in daily life with diabetes

Katarina Braune

Charité – Universitätsmedizin Berlin

Berlin, Germany

Data integration and security: Essential to optimise therapy within an open ecosystem

Olivier Convard

Roche Diabetes Care

Sant Cugat, Spain

Latest developments in insulin delivery: What’s new and next?

Julia Mader

Medical University of Graz

Graz, Austria

Abstracts & Posters

Continuous intraperitoneal insulin infusion shows a great benefit-risk ratio under long-term real-world use in a vulnerable population with diabetes

Continuous intraperitoneal insulin infusion shows a great benefit-risk ratio under long-term real-world use in a vulnerable population with diabetes

  • Session: Different aspects on type 2 therapies – Poster Hall

  • Author: Gehr et al.

Long-term safety of the Eversense® CGM system: PMCF registry

Long-term safety of the Eversense® CGM system: PMCF registry

  • Session: Technologies to measure glucose – Poster Hall

  • Author: Kaufman et al.

The cost-effectiveness of the PDM - ProValue Diabetes Management programme in Germany

The cost-effectiveness of the PDM – ProValue Diabetes Management programme in Germany

  • Session: Making diabetes care more cost-effective – Poster Hall

  • Author: Schramm et al.

Get all Publications and Solutions Brochures via E-Mail

Order Now

Publications:

Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control: First results from the ABACUS trial
(Ziegler et al. Diabetes Care. 2013 Nov;36(11):3613-9.)
Use of an Automated Bolus Calculator in MDI-Treated Type 1 Diabetes - The BolusCal Study, a randomized controlled pilot study
(Schmidt et al. Diabetes Care. 2012 May;35(5):984-90.)
System Accuracy Evaluation of 43 Blood Glucose Monitoring Systems for Self-Monitoring of Blood Glucose According to DIN EN ISO 15197
(Freckmann et al. J Diabetes Sci Technol. 2012 Sep 1;6(5):1060-75.)
Use of a Novel, Remotely Connected Diabetes Management System Is Associated with Increased Treatment Satisfaction, Reduced Diabetes Distress, and Improved Glycemic Control in Individuals with Insulin-Treated Diabetes: First Results from the Personal Diabetes Management Study
(Mora et al. Diabetes Technol Ther. 2017 Dec 1; 19(12): 715–22.)
Evaluation of a new digital automated glycemic pattern detection tool
(Comellas et al. Diabetes Technol Ther. 2017 Nov 1; 19(11): 633–40.)
Use of Diabetes Data Management Software Reports by Health Care Providers, Patients With Diabetes, and Caregivers Improves Accuracy and Efficiency of Data Analysis and Interpretation Compared With Traditional Logbook Data: First Results of the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES)
(Hinnen et al. J Diabetes Sci Technol. 2015 Mar;9(2):293-301.)
What Do We Need beyond Hemoglobin A1c to Get the Complete Picture of glycemia in people with diabetes?
(Hinzmann et al. Int J Med Sci. 2012;9(8):665-81)
Boluses in insulin therapy
(Ziegler et al. J Diabetes Sci Technol 2017; 11(1):165-71.)
Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study
(Steineck et al. BMJ 2015; 350: h3234.)
Open Source Closed-Loop Insulin Delivery Systems: A Clash of Cultures or Merging of Diverse Approaches?
(Barnard et al. J Diabetes Sci Technol. 2018 Nov;12(6):1223-1226)
Patch Pumps: Are They All the Same?
(Heinemann et al. J Diabetes Sci Technol. 2019 Jan;13(1):34-40.)
Establishing methods to determine clinically relevant bolus and basal rate delivery accuracy of insulin pumps
(Kamecke et al. J Diabetes Sci Technol 2018; ePub)
Occlusion detection time in insulin pumps at two different basal rates
(Freckmann et al. J Diabetes Sci Technol 2018 ;12(3):608–613)
Continuous subcutaneous insulin infusion: Special needs for children
(Adolfsson et al. Pediatr Diabetes. 2017 Jun;18(4):255-261)
Using insulin pump with a remote-control system in young patients with diabetes improves glycemic control and enhances patient satisfaction
(Deeb et al. Clin Diabetes Endocrinol. 2019 Jun 6;5:7.)
Accuracy of bolus and basal rate delivery of different insulin pump systems
(Freckmann et al. Diabetes Technol Ther. 2019 Apr;21(4):201-208.)
Comparative handling analysis of different insulin pump systems
(Waldenmaier et al. J Diabetes Sci Technol. 2018 Mar; 12(2): 401–406.)
Concept and implementation of a novel patch pump for insulin delivery
(Ulbrich et al. J Diabetes Sci Technol. 2019 Aug [epub])
A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II
(Christiansen et al. Diabetes Technol Ther. 2018 Jan 30 (Epub))
Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial
(Kropff et al. Diabetes Care. 2017 Jan;40(1):63-68.)
(Heinemann et al. J Diabetes Sci Technol. 2019 Jun [epub])
Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice
(Johnson et al. J Diabetes Sci Technol. 2019 Jun;21(S2):S217-S225.)
Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program
(Kulzer et al. Diab Res Clin Pract. 2018 Oct;144:200-212)
Integrated Personalized Diabetes Management (PDM): Design of the ProValue Studies: Prospective, Cluster-Randomized, Controlled, Intervention Trials for Evaluation of the Effectiveness and Benefit of PDM in Patients With Insulin-Treated Type 2 Diabetes.
(Kulzer et al. J Diabetes Sci Technol. 2016 May 3;10(3):772-81.)
PDM-ProValue meets cardiovascular outcome trials in diabetes
(Fritzen et al. Cardiovasc Diabetol. 2019 Jan 28;18(1):10)
Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data
(Ravizza et al. Nat Med. 2019 Jan;25(1):57-59.)
A New Optimized Percutaneous Access System for CIPII
(Garcia-Verdugo et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study.
(Dassau et al. Diabetes Obes Metab. 2017 Dec;19(12):1698-1705.)
Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes.
(Pasquini et al. Acta Diabetol. 2019 Aug 9.)
New design of a percutaneous port system for continuous intraperitoneal insulin infusion
(Rieger et al. J Diabetes Sci Technol. 2019 Jun [epub])
Utilizing eHealth and telemedicine technologies to enhance access and quality
(Barnard et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
A digital-first model of diabetes care
(Cafazzo et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Real-world assessments of mySugr mobile health app
(Debong et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Use of artificial intelligence to improve diabetes outcomes in patients using multiple daily injections therapy
(Forlenza et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
The emerging role of telemedicine and mobile health technologies in improving diabetes care
(Garg et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Current status and future directions for electronic point-of-care clinical decision support
(O’Connor et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Use of telemedicine technologies in diabetes prevention and control in resource-constrained settings - lessons learned from emerging economies
(Pradeepa et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Virtual coaching to enhance diabetes care
(Ramchandani et al. J Diabetes Sci Technol. 2017 Jul;11(4):814-821.)
Twelve-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin a1c and hypoglycemia.
(Dassau et al. Diabetes Care. 2017 Dec;40(12):1719-1726.)
Closed-loop control during intense prolonged outdoor exercise in adolescents with type 1 diabetes: the artificial pancreas ski study.
(Breton et al. Diabetes Care. 2017 Dec;40(12):1644-1650.)
Overnight closed-loop control improves glycemic control in a multicenter study of adults with type 1 diabetes
(Brown et al. Clin Endocrinol Metab. 2017 Oct 1;102(10):3674-3682.)
Closed-loop control without meal announcement in type 1 diabetes.
(Cameron et al. Diabetes Technol Ther. 2017 Sep;19(9):527-532.)
Artificial pancreas: clinical study in latin america without premeal insulin boluses.
(Sanchez-Pena et al. J Diabetes Sci Technol. 2018 Sep;12(5):914-925.)
Day-and-night closed-loop control using the unified safety system in adolescents with type 1 diabetes at camp.
(Ly et al. Diabetes Care. 2016 Aug;39(8):e106-7.)
Outpatient closed-loop control with unannounced moderate exercise in adolescents using zone model predictive control
(Huyett et al. Diabetes Technol Ther. 2017 Jun 1; 19(6): 331–339.)
Modeling of Diabetes and Its Clinical Impact
(Fritzen et al. J Diabetes Sci Technol. 2018 Sep;12(5):976-984.)

Brochures - Our Solutions:

Accu-Chek® Solo

  • First detachable and tube-free insulin pump
  • Unique quick bolus buttons on pump
  • Diabetes Manager with open bolus advice to combine therapy with continuous glucose monitoring solutions

mySugr

  • Quick, automated, easy-to-understand logging of BG levels, via Bluetooth
  • Automatic data integration of leading BG meters (e.g. Accu-Chek Guide), CGM devices (e.g. Eversense), and soon smart pens
  • Bolus advice
  • Easy-to-read reports
  • Personal diabetes coach

Eversense®

  • Up to 6 months wearing time
  • Removable smart transmitter with on-body vibe alerts
  • Predictive alerts before reaching low or high glucose levels
  • Simple, 5-minute in-office insertion
  • Wireless data connection to mySugr

Accu-Chek® Smart Pix Online

  • Provides quick insights into key diabetes data
  • Helps with patient understanding of lifestyle and therapy
  • Enables rapid identification of patients not adhering to therapy or needing attention

Accu-Chek® SugarView

  • All you need is a smartphone, an Accu-Chek Active blood glucose test strip, a lancet, and the app to see your blood glucose test range and know what to do next.
  • Feel motivated and assured about your type 2 diabetes as you know your next step.
  • Know how you are doing in between your doctor’s appointments in an affordable way.

Accu-Chek® Guide

  • Easy-to-remove test strips with spill-resistant SmartVial
  • Strip port light, wide, easy-edge test strip, and meter strip ejection
  • Wireless transmission of results to mySugr app

Accu-Chek® Smart Pix

  • Open version allows for read-out of devices from Roche and other manufacturers
  • All data seamlessly available in one system
  • Easy and fast conclusions and therapy adaptations possible
  • Easily understandable visualization of different diabetes-relevant data

Accu-Chek® Insight

  • Intuitive & discreet: Diabetes manager with full remote control with bolus advice, and accurate insulin delivery
  • Easy & safe: Pre-filled cartridge, no air bubbles to remove, sensitive occlusion detection

Accu-Chek® Instant

  • Target Range Indicator – For instant clarity on results
  • Easy navigation – Only 1 button needed!
  • Easy-edge dosing – Wide blood application area compared to leading brands
  • Connection to mySugr app – No more manual diaries